Zentalis Pharmaceuticals Inc(ZNTL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.96 | Insider Own | 29.14% | Shs Outstand | 71.7M | Perf Week | -10.63% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | 10.05% | Insider Trans | 18.64% | Shs Float | 67.1M | Perf Month | -26.59% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.54 | Inst Own | 41.93% | Short Float | 8.92% | Perf Quarter | -62.09% |
| Income | -0.14B | P/S | - | EPS this Y | -9.37% | Inst Trans | 1.73% | Short Ratio | 4.95 | Perf Half Y | -53.75% |
| Sales | 0.00B | P/B | 0.92 | EPS next 5Y | 3.75% | ROA | -49.22% | Short Interest | 5.99M | Perf YTD | 37.04% |
| Book/sh | 2 | P/C | 1 | EPS past 3/5Y | 24.78% 7.86% | ROE | -66.75% | 52W High | -73.38% ($6.95) | Perf Year | 23.33% |
| Cash/sh | 1.84 | P/FCF | - | Sales past 3/5Y | - | ROIC | -78.75% | 52W Low | 52.64% ($1.21) | Perf 3Y | -88.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.08% | Gross Margin | - | Volatility(W/M) | 7.34% 7.66% | Perf 5Y | -97.71% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.82 | EPS Q/Q | -58.83% | Profit Margin | - | RSI (14) | 28.64 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.82 | Sales Q/Q | - | SMA20 | -18.79% ($2.28) | Beta | 1.92 | Target Price | $7.7 |
| Payout | - | Debt/Eq | 0.26 | Earnings | 2026/8/6 | SMA50 | -36.37% ($2.91) | Rel Volume | 0.89 | Prev Close | $1.96 |
| Employees | 106 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | -20.41% - | SMA200 | -46.33% ($3.45) | Avg Volume(3M) | 1.21M | Price | $1.85 |
| IPO | 2020/4/3 | Option/Short | Yes/Yes | Trades | 2840 | Volume | 1,074,052 | Change | -5.61% |
🧬 This is a US clinical-stage biotech company developing novel anti-cancer drugs. Its core pipeline is the oral candidate azenosertib, which targets a cell cycle regulatory protein, with a focus on developing therapeutics for solid tumors, including ovarian cancer.
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
ZNTL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -9.4% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.7%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 41.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #313 of 597 in the industry
Based on market cap of $175M.
WHWK#312 Whitehawk Therapeutics Inc $178M PER - ZNTL#313 Zentalis Pharmaceuticals Inc $175M PER - 
MDWD#314 MediWound Ltd $174M PER - 
IVVD#315 Invivyd Inc $172M PER - 
YARW#316 Yarrow Bioscience Inc $169M PER - 
FAQ
What kind of company is ZNTL?
ZNTL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ZNTL?
The market cap of ZNTL is approximately $175M, ranking 4,100 within its sector.
What is the 52-week high and low for ZNTL?
ZNTL has recorded a 52-week high of $6.95 and a low of $1.21.
